Abstract
Contemporary polyethylene liners for total hip replacements were introduced in the late 1990's to address osteolysis associated with wear of conventional polyethylene. Every major device manufacturer introduced an “enhanced polyethylene”. In the ensuing decade plus, every major arthroplasty meeting had presentations and debates about the wear resistance and mechanical properties of these new polymers. The results have been remarkable and now with 17 to 18 years of use in patients, we have yet to see clinically significant osteolysis in our patients regardless age or activity level.
The results can be summarised as follows: All currently commercially available highly crosslinked polyethylenes produced by major device companies have demonstrated a reduction in wear and osteolysis. At the 2016 Closed Meeting of The Hip Society, none of the surgeons attending had seen a clinically significant case of osteolysis associated with highly crosslinked polyethylene. Registry data demonstrates the superiority of the highly crosslinked materials over conventional polyethylenes.
Historical concerns over a reduction in mechanical properties have not been borne out in clinical studies. Although highly crosslinked polyethylene liner fractures have been reported, they are rare and probably related to specific designs or surgical technique issues. It is important to remember that there were rare cases of fracture of conventional polyethylene as well.
With currently reported wear rates of the enhanced polyethylenes, polyethylene thickness is unlikely to be a factor in long-term durability with well-designed sockets. Bench data has demonstrated that polyethylene thickness is not a risk factor for wear or fracture if well supported by the metal shell. Thin unsupported polyethylene is at risk for fracture.
Although the new anti-oxidant polyethylenes (eg. Vitamin E) have performed well in wear studies, there is no clinically available evidence to support their use based on enhanced fracture toughness.
